UBS O'Connor’s Syndax Pharmaceuticals SNDX Stock Holding History

UBS O'Connor’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$25K	–	447
2024 Q4	$25K	Buy	+100,000	New	+$1.71M	﹤0.01%	379

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

UBS O'Connor's SNDX Position: Q3 2025 in Review

UBS O'Connor sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 90,441 shares — an estimated $847K sold.

UBS O'Connor first reported a position in SNDX in Q4 2023 and held it in 7 quarters. The position peaked at $2.58M in Q1 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

UBS O'Connor reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 90,441 Syndax Pharmaceuticals shares in Q3 2025, an estimated $847K.
UBS O'Connor first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 7 quarters.
UBS O'Connor's Syndax Pharmaceuticals position peaked at $2.58M in Q1 2024.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.